PHILOGEN S.P.A. financials
PHILOGEN S.P.A.
81560009EA1577917768 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €320.1M | €77.7M |
| Operating expenses | €62.7M | €39.9M |
| Employee benefits expense | €17.9M | €15.6M |
| Raw materials & consumables used | €5.3M | €3.1M |
| Depreciation & amortisation | €4.3M | €3.9M |
| Operating profit (EBIT) | €257.4M | €37.7M |
| Net finance income / (cost) | €2.7M | €2.6M |
| Finance costs | €8.2M | €3.3M |
| Profit before tax | €260.1M | €40.4M |
| Income tax expense | €30.4M | -€4.9M |
| Profit for the year | €229.7M | €45.3M |
| — attributable to owners | €229.7M | €45.3M |
| — attributable to NCI | €5.0K | €0 |
| Total comprehensive income | €231.1M | €45.0M |
| Per share | ||
| Basic EPS | €5.70 | €1.12 |
| Diluted EPS | €5.70 | €1.12 |
| Free cash flow / share | €6.57 | €0.96 |
| Cash flow statement | ||
| Net cash from operating activities | €268.0M | €40.8M |
| Income taxes paid | €0 | €0 |
| Net cash from investing activities | -€168.3M | -€22.3M |
| Purchase of PP&E (capex) | €3.4M | €2.2M |
| Purchase of intangibles | €241.0K | €245.0K |
| Net cash from financing activities | -€3.0M | -€3.8M |
| Proceeds from borrowings | €0 | €0 |
| Repayments of borrowings | €0 | €2.8M |
| Lease liability payments | €1.2M | €992.0K |
| Net change in cash | €95.9M | €14.8M |
| Balance sheet | ||
| Total assets | €437.3M | €168.5M |
| Non-current assets | €39.5M | €36.1M |
| Property, plant & equipment | €16.0M | €15.5M |
| Right-of-use assets | €8.8M | €9.4M |
| Current assets | €397.9M | €132.3M |
| Inventories | €3.0M | €3.3M |
| Trade & other receivables | €1.3M | €760.0K |
| Cash & equivalents | €127.2M | €30.6M |
| Total equity | €373.9M | €138.7M |
| — attributable to owners | €373.9M | €138.7M |
| Non-controlling interests | €5.0K | €0 |
| Non-current liabilities | €12.2M | €13.2M |
| Lease liabilities (non-current) | €9.7M | €10.5M |
| Current liabilities | €51.3M | €16.6M |
| Lease liabilities (current) | €1.2M | €1.0M |
| Deferred tax liabilities | €407.0K | €283.0K |
| Derived metrics | ||
| Free cash flow | €264.6M | €38.7M |
| Operating margin | 80.4% | 48.6% |
| Net margin | 71.7% | 58.3% |
| Return on equity | 61.4% | 32.7% |
| Cash conversion ratio | 1.17× | 0.90× |
| Capex coverage | 78.98× | 18.85× |
| Other reported items | ||
| Adjustments For Amortisation Expense | €4.3M | €3.9M |
| Adjustments For Decrease Increase In Contract Assets | €325.0K | -€1.9M |
| Adjustments For Decrease Increase In Inventories | €281.0K | -€1.0M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€228.0K | €802.0K |
| Adjustments For Finance Income Cost | €2.7M | €2.6M |
| Adjustments For Income Tax Expense | €30.4M | -€4.9M |
| Adjustments For Increase Decrease In Contract Liabilities | €1.2M | €174.0K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €299.0K | €273.0K |
| Adjustments For Increase Decrease In Trade Account Payable | €3.5M | €1.8M |
| Adjustments For Sharebased Payments | €6.1M | €2.9M |
| Comprehensive Income Attributable To Owners of Parent | €231.1M | €45.0M |
| Current Contract Assets | €2.9M | €3.3M |
| Current Contract Liabilities | €1.8M | €643.0K |
| Current Financial Liabilities | €44.0K | €37.0K |
| Current Tax Assets Current | €10.4M | €10.3M |
| Current Tax Liabilities Current | €31.3M | €2.1M |
| Deferred Tax Assets | €9.1M | €8.5M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €721.0K | €158.0K |
| Equity and Liabilities | €437.3M | €168.5M |
| Finance Income | €10.9M | €5.9M |
| Gains Losses On Cash Flow Hedges Before Tax | €0 | -€200.0K |
| Gains Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income Net of Tax | -€213.0K | €127.0K |
| Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income | €0 | -€56.0K |
| Income Tax Relating To Share of Other Comprehensive Income of Associates and Joint Ventures Accounted For Using Equity Method That Will Not Be Reclassified To Profit Or Loss | -€44.0K | €28.0K |
| Increase Decrease In Cash and Cash Equivalents | €96.6M | €14.8M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | -€179.0K | €213.0K |
| Intangible Assets Other Than Goodwill | €1.1M | €1.2M |
| Interest Paid Classified As Operating Activities | -€1.0M | €665.0K |
| Interest Received Classified As Investing Activities | €3.5M | €1.8M |
| Issue of Equity | €6.1M | €2.9M |
| Issued Capital | €5.7M | €5.7M |
| Liabilities | €63.5M | €29.8M |
| Noncurrent Financial Liabilities | — | €0 |
| Noncurrent Provisions For Employee Benefits | €1.3M | €1.3M |
| Other Adjustments For Noncash Items | €1.1M | -€769.0K |
| Other Comprehensive Income | €1.5M | -€263.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €1.6M | -€208.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €27.0K | -€10.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €1.6M | -€352.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€142.0K | €89.0K |
| Other Current Assets | €1.1M | €1.1M |
| Other Current Financial Assets | €252.0M | €83.2M |
| Other Current Liabilities | €3.9M | €3.2M |
| Other Expense By Nature | €463.0K | €498.0K |
| Other Noncurrent Assets | €4.4M | €1.6M |
| Other Noncurrent Liabilities | €717.0K | €1.1M |
| Other Reserves | €45.7M | -€5.5M |
| Other Revenue | €5.8M | €3.7M |
| Payments To Acquire Or Redeem Entitys Shares | €1.8M | €27.0K |
| Proceeds From Issuing Shares | €0 | €0 |
| Purchase of Financial Instruments Classified As Investing Activities | €213.5M | €47.3M |
| Purchase of Treasury Shares | €1.8M | €27.0K |
| Rental Expense | €573.0K | €338.0K |
| Retained Earnings Profit Loss For Reporting Period | €229.7M | €45.3M |
| Revenue From Contracts With Customers | €314.3M | €74.0M |
| Services Expense | €34.3M | €16.5M |
| Share Premium | €92.8M | €93.1M |
| Trade and Other Current Payables To Trade Suppliers | €13.0M | €9.6M |
Every line item above is a fact tagged in PHILOGEN S.P.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.